Related Experiment Video

Updated: Aug 6, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

[Medication reducing therapy of atrial fibrillation: a new approach to an old problem]

A V Nedostup, O V Blagova, E A Bogdanova

    Terapevticheskii Arkhiv
    |October 4, 2002
    PubMed

    Insights

    Combined therapy effectively manages chronic atrial fibrillation (CAF) by optimizing heart rate control. Drug selection and dosage depend on atrial electrical activity and ventricular rhythm structure for best results.

    Area of Science:

    • Cardiology
    • Electrophysiology

    Context:

    • Chronic atrial fibrillation (CAF) presents challenges in managing ventricular rate and rhythm.
    • Understanding the impact of rate-reducing medications on atrial and ventricular activity is crucial for effective treatment.

    Purpose:

    • To investigate how different classes of rate-reducing medications influence atrial electrical activity and ventricular rhythm in patients with CAF.
    • To optimize therapeutic strategies for CAF based on drug-specific effects and patient electrophysiological characteristics.

    Summary:

    • This study analyzed 57 CAF patients treated with digitalis, beta-blockers, combinations, verapamil, amiodarone, and sotalol using high-resolution ECG.
    • Results indicate that the ff-wave period (0.12-0.20s) and AV conduction dictate ventricular response.
    • Digitalis primarily reduces heart rate by shortening the ff-wave period, with AV block occurring later in therapy.

    Impact:

    • Combined therapy with drugs having diverse mechanisms offers the highest efficiency in CAF management.
    • Tailoring medication choice and dosage to individual ff-wave periods and ventricular rhythm structure is essential for optimizing patient outcomes.
    Abstract

    More Related Videos

    Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

    Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

    Published on: February 26, 2013

    Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology10:46

    Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

    Published on: May 26, 2015

    Related Concept Videos

    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

    Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    Dysrhythmias VI: Management of Dysrhythmias01:25

    Dysrhythmias VI: Management of Dysrhythmias

    Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
    Atherosclerosis III: Management01:26

    Atherosclerosis III: Management

    Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
    Drug Therapy01:28

    Drug Therapy

    The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
    Antianxiety Medications